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The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a number of EGFR-targeted agents have
been developed. Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib (‘Iressa’, ZD1839) and
erlotinib (‘Tarceva’, OSI-774), and the monoclonal antibody cetuximab (‘Erbitux’, IMC-C225). This review provides a clinical overview
of these agents, highlighting their antitumour activities in different tumour types. Epidermal growth factor receptor–targeted agents
are generally well tolerated and are not typically associated with the severe adverse events often seen with cytotoxic chemotherapy.
Gefitinib is the agent with the most extensive clinical experience, particularly in non-small-cell lung cancer (NSCLC). Recently, gefitinib
became the first-approved EGFR-targeted agent, for use in patients with previously treated advanced NSCLC in Japan, the USA and
other countries. Further studies are required to explore the full potential of these novel agents either as monotherapy or combination
therapy.
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Conventional cytotoxic anticancer agents have limited efficacy and
a narrow therapeutic index. Identification of molecular targets
important for cancer cell proliferation and survival has provided
an opportunity for improved efficacy and more selective action; on
tumour rather than normal tissue (Baselga, 2002; Herbst and Kies,
2002).
One such target is the epidermal growth factor receptor (EGFR),
which is highly expressed in a variety of solid tumours. Expression
correlates with disease progression, poor survival, poor response
to therapy and resistance to cytotoxic agents (Arteaga, 2002). The
EGFR is a transmembrane glycoprotein comprising an extracel-
lular ligand-binding domain, a transmembrane hydrophobic
domain and an intracellular domain with tyrosine kinase activity
involved in signal transduction (Figure 1). Upon ligand binding,
receptor dimerisation activates tyrosine kinase activity and
tyrosine autophosphorylation. This initiates a signalling cascade
that leads to cell proliferation, increased angiogenesis, invasion
and metastasis and decreased apoptosis (Baselga, 2002).
A variety of strategies to target EGFR signalling have been
investigated, including: (1) small molecule tyrosine kinase
inhibitors that prevent ATP from binding to the intracellular
tyrosine kinase domain of EGFR, thereby inhibiting tyrosine
kinase activity and autophosphorylation, and subsequent signal
transduction; (2) monoclonal antibodies that target the extra-
cellular ligand-binding domain or bispecific antibodies that also
target epitopes on the surface of immune effector cells; (3)
immunotoxin conjugates using cytotoxic single-chain fragment
variable antibodies conjugated to toxins such as pseudomonas
endotoxin A; (4) EGF vaccines such as EGF-P64k that contained
recombinant human EGF conjugated to P64k, a highly immuno-
genic recombinant bacterial protein; (5) antisense oligonucleotides
to block the translation of the ligand or the EGFR (Figure 1)
(Baselga, 2002). The first two of these approaches have proved to
be the most successful (Table 1).
This review will concentrate on the agents most advanced in
clinical development: the EGFR tyrosine kinase inhibitors gefitinib
(‘Iressa’, ZD1839) and erlotinib (‘Tarceva’, OSI-774), and the
chimeric human–mouse monoclonal antibody cetuximab (‘Erbi-
tux’, IMC-C225) (Table 2). Gefitinib has recently received
approval, the first for an EGFR-targeted agent, for the treatment
of patients with previously treated advanced non-small-cell lung
cancer (NSCLC) in Japan, the USA and other countries. Erlotinib is
currently in the follow-up stage of three large Phase III trials and
cetuximab is at the pre-registration stage for colorectal cancer.
PRECLINICAL DATA
As monotherapy, gefitinib, erlotinib and cetuximab were anti-
proliferative and increased apoptosis in different cancer cell lines
and human tumours xenografted to immunodeficient mice
(Ciardiello et al, 2000; Ciardiello and Tortora, 2001). Interestingly,
although there was a spectrum of dose-dependent antitumour
activity ranging from dramatic tumour regression to de novo
resistance when gefitinib was tested in multiple human tumour
xenograft studies, the level of EGFR expression did not predict
tumour response (Wakeling et al, 2002). Many studies demon-
strated additive or synergistic antitumour effects when combining
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other novel agents (Milas et al, 2000; Sirotnak et al, 2000; Tortora
et al, 2001; Bianco et al, 2002; Buchsbaum et al, 2002; Huang et al,
2002; Magne et al, 2002; Normanno et al, 2002; Williams et al,
2002; Prewett et al, 2003; Solomon et al, 2003; Xu et al, 2003).
CLINICAL OVERVIEW
Epidermal growth factor receptor-targeted agents have been
investigated in several human cancers. Many studies have involved
patients with tumours that widely express EGFR, including NSCLC,
colorectal cancer, squamous-cell carcinoma of the head and neck
(SCCHN) and breast cancer. Existing treatments improve survival
times, but many patients with advanced disease relapse and
require further therapy to palliate symptoms and improve survival.
This highlights the significant unmet need for novel, targeted
agents (Herbst and Kies, 2002; O’Dwyer and Benson, 2002; Herbst
and Langer, 2002; Cohen, 2003; Cohen et al, 2003a).
Gefitinib
Four multicentre, open-label, Phase I trials investigated the
tolerability and efficacy of oral gefitinib (up to 1000mgday
 1)i n
patients with a variety of solid tumours, including NSCLC (Baselga
et al, 2002; Herbst et al, 2002; Ranson et al, 2002; Nakagawa et al,
2003). As gefitinib is not a traditional cytotoxic agent, dose
selection for further study was based on identification of the
optimum biological dose, combining maximum efficacy with
minimum adverse events (AEs).
Gefitinib was generally well tolerated; the most common AEs
were mild/moderate (grade 1/2) reversible rash and diarrhoea,
whose incidence and severity increased with increasing dose.
Gefitinib was not typically associated with the cytotoxic AEs of
chemotherapy. The maximum tolerated dose (MTD) was
X700mgday
 1. Promising antitumour activity was observed in a
number of tumour types, particularly NSCLC; 10 out of 100 NSCLC
patients experienced a partial tumour response (Herbst et al, 2002;
Ranson et al, 2002; Nakagawa et al, 2003). Partial responses and
disease stabilisation were observed at doses X150mgday
 1 with
no suggestion that higher doses provided greater antitumour
activity (Herbst and Kies, 2002; Ranson et al, 2002). Similarly, pre-
and post-treatment skin biopsy results from cancer patients
revealed that EGFR signalling was inhibited at doses
X150mgday
 1, with no clear dose dependence above this level
(Albanell et al, 2002). Based on these results, two doses below the
MTD were chosen for evaluation in Phase II studies: 250mgday
 1,
at which dose responses had been seen with minimum toxicity,
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Figure 1 EGFR signalling and anti-EGFR approaches (reproduced with
permission from: Baselga (2002); rAlphaMed Press 1083–7159).
Table 1 EGFR-targeted therapies in clinical development
Class of agent Agent
Phase of
development
EGFR tyrosine kinase inhibitors
Gefitinib, ZD1839 III/marketed
Erlotinib, OSI-74 III
Canertinib, CI-1033 II
EKB-569 II
Lapatinib, GW572016 II
Monoclonal antibodies
Human–murine chimeric
monoclonal antibodies
Cetuximab, IMC-C225 III/pre-registration
Fully humanised monoclonal
antibodies
ABX-EGF II
EMD-72000 II
Thera CIM-h-R3 II
HuMax-EGFR I/II
Table 2 Clinical development of gefitinib, erlotinib and cetuximab
Agent
Class of
agent Phase I trial design MTD
Dose selection
parameters
Dose selected
for further study
Tumour
types
Phase of
development
Gefitinib EGFR-TKI Monotherapy up
to 1000mgday
 1
X700mgday
 1 Optimum biological dose:
tumour response/stable
disease, target activity
and pharmacokinetics
250 and 500mgday
 1 NSCLC,
SCCHN,
colorectal,
breast
III/marketed
(NSCLC)
Erlotinib EGFR-TKI Three monotherapy regimens
(100–1600mg) administered:
once weekly every 3 out
of 4 weeks; 3 consecutive
days for 3 weeks;
daily for 3 weeks
150mgday
 1 MTD 150mgday
 1 NSCLC,
SCCHN,
pancreatic
III (NSCLC,
pancreatic)
Cetuximab Monoclonal
antibody
Administered intravenously
as single infusion (5–100mgm
 2);
weekly for 4 weeks
(5–100mgm
 2); weekly for
4 weeks combined
with cisplatin (400mg/m
2)
Saturates systemic
clearance,
200–400mgm
 2
Optimum biological dose:
pharmacokinetics,
EGFR saturation
Loading dose
400mgm
 2 in week 1
followed by weekly
maintenance dose
of 250mgm
 2
SCCHN,
colorectal,
NSCLC
III/preregistration,
(SCCHN, colorectal)
MTD¼maximum tolerated dose; NSCLC¼non-small-cell lung cancer; SCCHN¼squamous-cell carcinoma of the head and neck.
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 1, the highest dose that has been tolerated on
prolonged treatment.
Gefitinib monotherapy in NSCLC Two large-scale Phase II,
multicentre, dose-randomised, double-blind, parallel-group stu-
dies, Iressa Dose Evaluation in Advanced Lung Cancer (IDEAL) 1
and 2, evaluated gefitinib monotherapy (250 and 500mgday
 1)i n
patients with locally advanced or metastatic NSCLC who had
received platinum-based chemotherapy (Fukuoka et al, 2003; Kris
et al, 2003). Doses were given daily until disease progression or
withdrawal due to intolerable toxicity. Patients in IDEAL 1 were
recruited from Europe, Japan, Australia and South Africa (103
patients at 250mgday
 1; 106 patients at 500mgday
 1) and must
have received one or two prior chemotherapy regimens, at least
one of which contained platinum. Patients in IDEAL 2 were
recruited from the USA (102 patients at 250mgday
 1; 114 patients
at 500mgday
 1), and must have received at least two prior
regimens including platinum and docetaxel given either concur-
rently or separately. Disease-related symptoms were measured
weekly using the independently validated Lung Cancer Subscale
(LCS) of the Functional Assessment of Cancer Therapy-Lung
(FACT-L) quality-of-life questionnaire (Cella et al, 2002). Using
the LCS, the severities of seven disease-related symptoms are
recorded on a five-point Likert scale where the maximum (best)
score possible is 28. All patients in IDEAL 2 were symptomatic,
with a baseline LCS score of p24 points.
Both doses showed clinically meaningful antitumour activity
with no greater efficacy at the higher dose (Figure 2). Adverse
events were fewer and less severe at the lower dose. Accordingly,
250mgday
 1 gefitinib (approximately one-third of the MTD) is
the recommended/optimum biological dose in NSCLC, causing
minimum AEs without compromising efficacy. Only results for
this dose will be discussed here. For IDEAL 1 and 2, respectively,
response rates were 18.4 and 11.8%, disease control rates were 54.4
and 42.2%, median progression-free survival was 2.7 and 1.9
months and median overall survival was 7.6 and 6.5 months.
Objective responses were achieved regardless of the number of
prior chemotherapy regimens.
Many patients’ disease-related symptoms improved signifi-
cantly, important because many NSCLC patients have frequent
and severe symptoms. Symptom improvement rates for IDEAL 1
and 2 were 40.3 and 43.1%, with a median time to improvement of
8 and 10 days, respectively. Symptom improvement correlated with
objective tumour response and was associated with increased
overall and progression-free survival (Herbst and Kies, 2002). In
IDEAL 2, the median overall survival for patients with symptom
improvement was 13.6 months, compared with 3.7 months for
patients without symptom improvement (Douillard et al, 2002).
In IDEAL 1 and 2, 24 and 34% of patients had an improved
quality of life, with a median time to improvement of 29 and 30
days, respectively. Most patients with a partial/complete response
or stable disease also showed improved quality of life (Natale and
Zaretsky, 2002).
The most common AEs were skin rash (47 and 43% in IDEAL 1
and 2, respectively) and diarrhoea (40 and 48%, respectively). The
majority of these AEs were Common Toxicity Criteria grade 1 and,
across both IDEAL 1 and 2, grade 3 diarrhoea and skin rash were
each observed in only one patient. The incidences of dose
reductions (o1%) and withdrawals (1.9 and 1.0% in IDEAL 1
and 2, respectively) due to AEs were also low (Schiller et al, 2002).
Gefitinib combination therapy in NSCLC Two Phase I trials
using carboplatin/paclitaxel and cisplatin/gemcitabine, respec-
tively, showed combination therapy to have acceptable tolerability
and no unexpected or cumulative toxicity (Miller et al, 2001;
Gonzalez-Larriba et al, 2002).
Two multinational, randomised, double-blind, placebo-con-
trolled Phase III studies investigated gefitinib combined with
standard platinum-based first-line chemotherapy regimens. The
‘Iressa’ NSCLC Trials Assessing Combination Treatment (IN-
TACT) 1 and 2 involved more than 2100 chemonaive patients with
advanced NSCLC (Giaccone et al, 2002; Johnson et al, 2002).
Disappointingly, there were no improvements in overall survival
or other efficacy outcomes in the first-line setting. However, these
placebo-controlled studies confirmed the favourable safety profile
of gefitinib observed in the IDEAL trials. The combination toxicity
profile was similar to that of chemotherapy alone except for the
addition of dose-dependent diarrhoea and skin rash.
Gefitinib therapy against other cancers A Phase II study
investigating gefitinib monotherapy (500mgday
 1) in patients
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Figure 2 Gefitinib antitumour activity in advanced NSCLC: IDEAL 1
and 2.
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mour activity and acceptable toxicity. Of 47 evaluable patients, the
response rate was 10.6% and the disease control rate 53%. The
median time to disease progression and overall survival were 3.4
and 8.1 months, respectively. This compares with median survival
times of 6–8 months from Phase III trials of other agents in this
setting. Skin toxicities, never greater than grade 2, were observed
in 48% of patients, and diarrhoea was observed in 50% of patients
(at grade 3 in three patients) (Cohen et al, 2003a). A Phase II trial
is recruiting patients (n¼63) with recurrent SCCHN to investigate
gefitinib monotherapy (250mgday
 1). Of the 14 patients currently
evaluable for response, four had stable disease. Toxicity was
assessed in 17 patients; the most common AEs were grade 1/2 rash
in 50% of patients and grade 1/2 diarrhoea in 20% of patients, with
no grade 3/4 AEs (Cohen et al, 2003b). Further data from this
patient population will be needed to determine whether 250 or
500mgday
 1 has optimum activity in recurrent SCCHN.
A Phase II study investigating combination therapy of gefitinib
(500mgday
 1) with FOLFOX-4, a triple-combination standard
treatment regimen for patients with advanced colorectal cancer,
showed antitumour activity. For untreated patients, the response
rate was 75% and for patients who had relapsed after chemother-
apy, 29%. These values compare with historical response rates of
30–55 and 9%, respectively. Combination therapy was generally
well tolerated with the most common grade 3/4 AE being diarrhoea
(Cho et al, 2003).
Two Phase II studies investigated gefitinib monotherapy
(500mgday
 1) in patients with advanced breast cancer. In the
first study (n¼31), 10 patients (32%) had stable disease for X3
months (Baselga et al, 2003). The second study involved nine
evaluable patients with acquired tamoxifen-resistant oestrogen-
receptor-positive breast cancer and 18 evaluable patients with
oestrogen-receptor-negative breast cancer. Of the tamoxifen-
resistant patients, one patient had a partial response and five
had stable disease. Of the oestrogen-receptor-negative patients,
one patient had a partial response and one patient had stable
disease (Robertson et al, 2003).
Erlotinib
In Phase I trials involving pretreated patients with advanced solid
tumours including NSCLC, three monotherapy regimens were
administered (dose range 100–1600mg): once weekly every 3 out
of 4 weeks; on 3 consecutive days for 3 weeks; daily for 3 weeks.
The MTD was not reached in the once-weekly schedule and
diarrhoea was the dose-limiting toxicity in the once-daily schedule,
at 200mgday
 1 (Siu et al, 1999). Common AEs were skin rashes
and diarrhoea. Using conventional chemotherapy dose-selection
methods, 150mgday
 1 (MTD) was selected for Phase II studies
(Ciardiello and Tortora, 2001; Kim and Murren, 2002).
Erlotinib in NSCLC In a Phase II trial, 56 patients with EGFR-
positive NSCLC recurrent or progressive after platinum-based
chemotherapy received erlotinib monotherapy. At 12 weeks, 10.7%
had a confirmed partial response and 33.9% had stable disease.
Treatment was generally well tolerated and the most common AE
was a maculopapular acneiform rash in 78% of patients. No
patients discontinued treatment due to toxicity and only two
patients had dose reductions to 100mgday
 1 (Perez-Soler et al,
2001).
Current Phase III trials in NSCLC are investigating monotherapy
in refractory patients randomised to receive erlotinib or placebo
and first-line combination therapy with carboplatin/paclitaxel or
gemcitabine/cisplatin (Kim and Murren, 2002). Preliminary results
from the first-line combination trials have shown that combination
with erlotinib did not result in an improvement in overall survival
compared with chemotherapy alone.
Erlotinib and other cancers Erlotinib monotherapy has antitu-
mour activity in other tumour types. Out of 114 patients with
SCCHN, 78 were evaluable for response: 12.8% had a partial
response and 29.5% had disease stabilisation. The most common
AE (n¼114) was acneiform rash in 72% of patients (Senzer et al,
2001). Of 30 evaluable patients with pretreated advanced refractory
ovarian cancer, 6.7% had a partial response and 10% had disease
stabilisation at 5–6 months. Treatment was generally well tolerated
and rash was the most common AE, in 88% of patients (Finkler
et al, 2001).
A Phase III trial is investigating erlotinib (100mgday
 1) and
gemcitabine combination therapy in 800 patients with pancreatic
cancer (Kim and Murren, 2002).
Cetuximab
In three consecutive open-label Phase I trials, 52 patients with
advanced tumours expressing high levels of EGFR were adminis-
tered cetuximab intravenously as a single infusion (5–
100mgm
 2), weekly for 4 weeks (5–100mgm
 2) or weekly for 4
weeks (up to 400mgm
 2) combined with cisplatin. The MTD was
not reached in any study; toxicity was minimal and unrelated to
dose or number of cycles administered. Common AEs were skin
toxicities, fever and chills, asthenia, transient transaminase
elevations and nausea. Four patients had grade 3/4 AEs. One
patient receiving monotherapy had grade 3 aseptic meningitis.
When cetuximab was combined with cisplatin, one patient had
diarrhoea (grade 3), one patient had an anaphylactic reaction
(grade 3) and one patient had both epiglottitis (grade 3) and
dyspnoea (grade 4) (Baselga et al, 2000).
Cetuximab displays nonlinear pharmacokinetics and, due to its
long half-life, can be administered weekly (Herbst and Hong,
2002). In Phase Ib clinical trials, a loading dose of 400mgm
 2 at
week 1 followed by a weekly maintenance dose of 250mgm
 2
achieved almost complete saturation of EGFR in tumour tissue.
This was the recommended dose for Phase II and III clinical trials
(Shin et al, 2001).
Replacing the constant region of the original mouse monoclonal
antibody with the constant region of human IgG1 reduced
immunogenicity. However, 4–6% of patients experience a serious
allergic event within minutes of infusion and 2% have anaphylactic
reactions (O’Dwyer and Benson, 2002; Baselga, 2002).
Cetuximab combination therapy Combining cetuximab with
standard anticancer treatments in patients with SCCHN, colorectal
or pancreatic cancer did not increase toxicity (Needle, 2002).
A Phase I study combining different doses of cetuximab with
radiotherapy showed promising activity in therapy-naive patients
with advanced SCCHN. Of 15 patients, 86.7% had a complete and
13.3% a partial response (Robert et al, 2001). A Phase II study
investigated cetuximab/cisplatin combination therapy in patients
with SCCHN; 12% of 78 evaluable patients with disease refractory
to cisplatin responded (Kies and Harari, 2002). A Phase III study
recruited 121 patients with untreated SCCHN metastatic disease to
compare cisplatin and cetuximab combination therapy with
cisplatin and placebo. The response rate was higher in the
combination treatment group: 23 vs 9%. However, there was no
significant difference in time to tumour progression (4.1 and 3.4
months, respectively) or overall median survival (9.2 and 8.0
months, respectively). Toxicity data was available for 64 patients.
Grade 3/4 AEs were hypersensitivity (6%), neutropenia (17%) and
rash/desquamation (11%) (Burtness et al, 2002; Kies and Harari,
2002).
Cetuximab monotherapy vs cetuximab combined with
irinotecan was investigated in 329 EGFR-positive, irinotecan-
refractory patients with metastatic colorectal cancer. The response
rate for the 218 patients who received combination therapy was
17.9% and the median time to progression was 126 days. In
Gefitinib (‘Iressa’) and new EGFR inhibitors
G Blackledge and S Averbuch
569
British Journal of Cancer (2004) 90(3), 566–572 & 2004 Cancer Research UKcontrast, for monotherapy patients, these values were 9.9% and 45
days. The 65 AEs potentially related to treatment were consistent
with the safety profiles of the individual agents (Cunningham et al,
2003).
Cetuximab combination therapy with cisplatin/vinorelbine vs
cisplatin/vinorelbine alone is being investigated as first-line
treatment in patients with EGFR-positive advanced NSCLC.
Preliminary response rates for 18 and 17 patients are 50 and
29%, respectively. Only two serious AEs have been related to
treatment with cetuximab (Gatzemeier et al, 2003).
DISCUSSION
Of the EGFR-targeting agents discussed in this review, gefitinib has
undergone the most extensive clinical evaluation. While the agents
share many similarities, differences in their properties and
approach to clinical development might influence their clinical
profile.
Gefitinib and erlotinib are administered orally, once daily, so
would be more suitable for an outpatient setting. In contrast,
cetuximab is administered intravenously and, as it is a chimeric
human–mouse monoclonal antibody, it can cause allergic reac-
tions (Ciardiello and Tortora, 2001; Baselga, 2002). Other
monoclonal antibodies in clinical development are fully huma-
nised antibodies that do not generate human antimouse anti-
bodies, thereby reducing the risk of inducing hypersensitivity
reactions in patients and potentially prolonging their in vivo
lifetime.
Different approaches to dose selection have been used. As
gefitinib is not a cytotoxic agent, it does not need to be given at the
MTD. In NSCLC patients, the 250mgday
 1 recommended dose
(about one-third of the MTD) showed equivalent efficacy to
500mgday
 1, but was associated with fewer grade 3/4 AEs, dose
reductions, and withdrawals. This supports Phase I trials that show
flat dose–response curves for efficacy while AEs increase with
dose. Cetuximab is also dosed below the MTD, whereas erlotinib
has followed a conventional cytotoxic dose-selection process, with
dosing at the MTD.
All three agents have shown monotherapy activity although
there are less data for cetuximab. It is harder to assess the efficacy
of combination treatment over the activity of individual agents.
Some studies provide promising results, whereas others demon-
strate no advantage. Further studies are required to assess and
optimise combination treatment with these agents.
The most common AEs for these EGFR-targeting agents are rash
and diarrhoea and are higher for erlotinib, which is dosed at the
MTD. These agents are not associated with the typical cytotoxic
AEs affecting patients treated with chemotherapy (Ciardiello and
Tortora, 2001).
In Japan, interstitial lung disease (ILD) has been observed in
gefitinib-treated patients with an incidence of 1.7% (Inoue et al,
2003). This is higher than the worldwide reported incidence of 1%
in over 92000 patients treated (up to September 2003) and 0.38%
in 439000 patients treated as part of a compassionate-use
programme (Forsythe and Faulkner, 2003). The incidence might
be higher in Japanese patients due to greater awareness of ILD
compared with the rest of the world, differences in ILD definitions
or increased genetic susceptibility. In one retrospective study of
711 Japanese patients with lung cancer who had undergone
surgical resection, 7.5% had idiopathic pulmonary fibrosis, a type
of ILD (Kawasaki et al, 2002). Interstitial lung disease is a known
complication of chemotherapy and radiotherapy in patients with
lung cancer (Abid et al, 2001) and many patients with advanced
NSCLC have no further treatment options, so the benefits of
gefitinib treatment outweigh the risks of ILD.
Epidermal growth factor receptor-targeted agents have also
shown promise in the treatment of patients with bronchioalveolar
carcinoma (BAC), which is considered to be a subtype of
adenocarcinoma of the lung without pleural, stromal or vascular
invasion (World Health Organization classification). In a recent
presentation at the European Cancer Conference, 13 out of 52
evaluable patients (25%) with BAC had a partial response to
treatment with erlotinib (Patel et al, 2003). Similar results have
been shown for gefitinib, with response rates of 20% (first line)
and 12% (pretreated) reported in patients with advanced BAC
(West et al, 2003).
The use of targeted agents has raised the possibility of selecting
the patients most likely to respond to treatment. Although some
studies involving EGFR-targeted agents selected patients according
to EGFR expression, there is no evidence for an association
between EGFR levels and response to small-molecule EGFR-
targeted agents. Hence, there are no data to support EGFR
screening to select patients who would benefit from treatment
(Woodburn et al, 2000; Arteaga, 2002). As with conventional
chemotherapy, some clinical baseline characteristics were pre-
dictive of greater response rates, for example, response rates to
gefitinib were higher for women and patients with adenocarcinoma
(Schiller et al, 2003). However, responses were observed in all
groups. Further studies are required to identify the molecular
profiles that predict the patients most likely to benefit from
treatment with these agents.
CONCLUSIONS
As monotherapy or combination therapy, EGFR-targeted agents
have demonstrated promise in treatment of several tumour types.
The most extensive clinical experience has been with gefitinib
(492000 patients) and two large Phase II studies have demon-
strated clinically relevant antitumour activity in patients with
previously treated advanced NSCLC.
The EGFR agents discussed have favourable AE profiles and are
not typically associated with the heavy toxicity burden of
chemotherapy agents, allowing long-term treatment. The max-
imum efficacy for targeted agents occurs below toxic doses,
allowing both gefitinib and cetuximab to be administered at doses
lower than the MTD to maximise the benefit:risk ratio. Gefitinib is
the first EGFR agent to be approved for cancer treatment in Japan,
the USA and other countries.
These novel therapies offer new treatment strategies to cancer
patients with limited treatment options and further studies are
underway to explore their full potential.
‘Iressa’ is a trademark of the AstraZeneca group of companies,
‘Tarceva’ is a trademark of OSI Pharmaceuticals, Inc., ‘Erbitux’ is a
trademark of ImClone Systems Incorporated of New York.
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